Estudo randomizado | Em pacientes com doença de Parkinson não controlada por levodopa, os inibidores de MAO-B ou agonistas de dopamina como terapias adjuvantes foram associados com melhora nos índices de qualidade de vida do paciente, em comparação aos inibidores de COMT.

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial – JAMA Neurology

Comentário no Twitter

In poorly controlled #ParkinsonDisease, study found adding a COMT inhibitor to existing treatment is not as good as adding a MAOB inhibitor or dopamine agonist https://t.co/0GrA2YYMbI pic.twitter.com/d4VNnom2zk

— JAMA Neurology (@JAMANeuro) December 28, 2021